Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) (165)” [Gynecologic Oncology Volume 166, Supplement 1, August 2022, Page S98]